1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Genetic Acute Myeloid Leukemia (AML) Biomarker 1.2.3 Epigenetic Acute Myeloid Leukemia (AML) Biomarker 1.2.4 Proteomic Acute Myeloid Leukemia (AML) Biomarker 1.3 Market by Application 1.3.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hospitals 1.3.3 Cancer diagnostic Centers 1.3.4 Research Institutes 1.3.5 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Perspective (2017-2028) 2.2 Acute Myeloid Leukemia (AML) Biomarker Testing Growth Trends by Region 2.2.1 Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Region (2017-2022) 2.2.3 Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Region (2023-2028) 2.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market Dynamics 2.3.1 Acute Myeloid Leukemia (AML) Biomarker Testing Industry Trends 2.3.2 Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers 2.3.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market Challenges 2.3.4 Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue 3.1.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue (2017-2022) 3.1.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Players (2017-2022) 3.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue 3.4 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Concentration Ratio 3.4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in 2021 3.5 Acute Myeloid Leukemia (AML) Biomarker Testing Key Players Head office and Area Served 3.6 Key Players Acute Myeloid Leukemia (AML) Biomarker Testing Product Solution and Service 3.7 Date of Enter into Acute Myeloid Leukemia (AML) Biomarker Testing Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Type 4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Type (2017-2022) 4.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Type (2023-2028) 5 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Application 5.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Application (2017-2022) 5.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2017-2028) 6.2 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2017-2022) 6.3 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2017-2028) 7.2 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2017-2022) 7.3 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2017-2028) 8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2017-2022) 8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2017-2028) 9.2 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2017-2022) 9.3 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2017-2028) 10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2017-2022) 10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Abbott Laboratories 11.1.1 Abbott Laboratories Company Detail 11.1.2 Abbott Laboratories Business Overview 11.1.3 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Introduction 11.1.4 Abbott Laboratories Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) 11.1.5 Abbott Laboratories Recent Development 11.2 Novartis AG 11.2.1 Novartis AG Company Detail 11.2.2 Novartis AG Business Overview 11.2.3 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction 11.2.4 Novartis AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) 11.2.5 Novartis AG Recent Development 11.3 Thermo Fisher Scientific 11.3.1 Thermo Fisher Scientific Company Detail 11.3.2 Thermo Fisher Scientific Business Overview 11.3.3 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Introduction 11.3.4 Thermo Fisher Scientific Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) 11.3.5 Thermo Fisher Scientific Recent Development 11.4 Cancer Genetics Inc. 11.4.1 Cancer Genetics Inc. Company Detail 11.4.2 Cancer Genetics Inc. Business Overview 11.4.3 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction 11.4.4 Cancer Genetics Inc. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) 11.4.5 Cancer Genetics Inc. Recent Development 11.5 Sysmex Corporation 11.5.1 Sysmex Corporation Company Detail 11.5.2 Sysmex Corporation Business Overview 11.5.3 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Introduction 11.5.4 Sysmex Corporation Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) 11.5.5 Sysmex Corporation Recent Development 11.6 Epigenomics AG 11.6.1 Epigenomics AG Company Detail 11.6.2 Epigenomics AG Business Overview 11.6.3 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction 11.6.4 Epigenomics AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) 11.6.5 Epigenomics AG Recent Development 11.7 BioMerieux SA 11.7.1 BioMerieux SA Company Detail 11.7.2 BioMerieux SA Business Overview 11.7.3 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Introduction 11.7.4 BioMerieux SA Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) 11.7.5 BioMerieux SA Recent Development 11.8 Skyline DX B.V. 11.8.1 Skyline DX B.V. Company Detail 11.8.2 Skyline DX B.V. Business Overview 11.8.3 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction 11.8.4 Skyline DX B.V. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) 11.8.5 Skyline DX B.V. Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Genetic Acute Myeloid Leukemia (AML) Biomarker Table 3. Key Players of Epigenetic Acute Myeloid Leukemia (AML) Biomarker Table 4. Key Players of Proteomic Acute Myeloid Leukemia (AML) Biomarker Table 5. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 6. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2017-2022) & (US$ Million) Table 8. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region (2017-2022) Table 9. Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 10. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region (2023-2028) Table 11. Acute Myeloid Leukemia (AML) Biomarker Testing Market Trends Table 12. Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers Table 13. Acute Myeloid Leukemia (AML) Biomarker Testing Market Challenges Table 14. Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints Table 15. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue by Players (2017-2022) & (US$ Million) Table 16. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Players (2017-2022) Table 17. Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing as of 2021) Table 18. Ranking of Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Companies by Revenue (US$ Million) in 2021 Table 19. Global 5 Largest Players Market Share by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (CR5 and HHI) & (2017-2022) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Acute Myeloid Leukemia (AML) Biomarker Testing Product Solution and Service Table 22. Date of Enter into Acute Myeloid Leukemia (AML) Biomarker Testing Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Type (2017-2022) & (US$ Million) Table 25. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Type (2017-2022) Table 26. Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 27. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Type (2023-2028) Table 28. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Application (2017-2022) & (US$ Million) Table 29. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Application (2017-2022) Table 30. Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 31. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Application (2023-2028) Table 32. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2017-2022) & (US$ Million) Table 33. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2023-2028) & (US$ Million) Table 34. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2017-2022) & (US$ Million) Table 35. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2023-2028) & (US$ Million) Table 36. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2017-2022) & (US$ Million) Table 37. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2023-2028) & (US$ Million) Table 38. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2017-2022) & (US$ Million) Table 39. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2023-2028) & (US$ Million) Table 40. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2017-2022) & (US$ Million) Table 41. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2023-2028) & (US$ Million) Table 42. Abbott Laboratories Company Detail Table 43. Abbott Laboratories Business Overview Table 44. Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Product Table 45. Abbott Laboratories Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) & (US$ Million) Table 46. Abbott Laboratories Recent Development Table 47. Novartis AG Company Detail Table 48. Novartis AG Business Overview Table 49. Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Product Table 50. Novartis AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) & (US$ Million) Table 51. Novartis AG Recent Development Table 52. Thermo Fisher Scientific Company Detail Table 53. Thermo Fisher Scientific Business Overview Table 54. Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Product Table 55. Thermo Fisher Scientific Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) & (US$ Million) Table 56. Thermo Fisher Scientific Recent Development Table 57. Cancer Genetics Inc. Company Detail Table 58. Cancer Genetics Inc. Business Overview Table 59. Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Product Table 60. Cancer Genetics Inc. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) & (US$ Million) Table 61. Cancer Genetics Inc. Recent Development Table 62. Sysmex Corporation Company Detail Table 63. Sysmex Corporation Business Overview Table 64. Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Product Table 65. Sysmex Corporation Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) & (US$ Million) Table 66. Sysmex Corporation Recent Development Table 67. Epigenomics AG Company Detail Table 68. Epigenomics AG Business Overview Table 69. Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Product Table 70. Epigenomics AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) & (US$ Million) Table 71. Epigenomics AG Recent Development Table 72. BioMerieux SA Company Detail Table 73. BioMerieux SA Business Overview Table 74. BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Product Table 75. BioMerieux SA Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) & (US$ Million) Table 76. BioMerieux SA Recent Development Table 77. Skyline DX B.V. Company Detail Table 78. Skyline DX B.V. Business Overview Table 79. Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Product Table 80. Skyline DX B.V. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) & (US$ Million) Table 81. Skyline DX B.V. Recent Development Table 82. Research Programs/Design for This Report Table 83. Key Data Information from Secondary Sources Table 84. Key Data Information from Primary Sources List of Figures Figure 1. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Type: 2021 VS 2028 Figure 2. Genetic Acute Myeloid Leukemia (AML) Biomarker Features Figure 3. Epigenetic Acute Myeloid Leukemia (AML) Biomarker Features Figure 4. Proteomic Acute Myeloid Leukemia (AML) Biomarker Features Figure 5. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Application in 2021 & 2028 Figure 6. Hospitals Case Studies Figure 7. Cancer diagnostic Centers Case Studies Figure 8. Research Institutes Case Studies Figure 9. Others Case Studies Figure 10. Acute Myeloid Leukemia (AML) Biomarker Testing Report Years Considered Figure 11. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 12. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 13. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region: 2021 VS 2028 Figure 14. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Players in 2021 Figure 15. Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing as of 2021) Figure 16. The Top 10 and 5 Players Market Share by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in 2021 Figure 17. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 18. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2017-2028) Figure 19. United States Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 20. Canada Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2017-2028) Figure 23. Germany Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. France Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. U.K. Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. Italy Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Russia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Nordic Countries Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region (2017-2028) Figure 31. China Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Japan Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. South Korea Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Southeast Asia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. India Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Australia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2017-2028) Figure 39. Mexico Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Brazil Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2017-2028) Figure 43. Turkey Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Saudi Arabia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Abbott Laboratories Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) Figure 46. Novartis AG Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) Figure 47. Thermo Fisher Scientific Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) Figure 48. Cancer Genetics Inc. Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) Figure 49. Sysmex Corporation Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) Figure 50. Epigenomics AG Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) Figure 51. BioMerieux SA Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) Figure 52. Skyline DX B.V. Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2017-2022) Figure 53. Bottom-up and Top-down Approaches for This Report Figure 54. Data Triangulation Figure 55. Key Executives Interviewed

Abbott Laboratories Novartis AG Thermo Fisher Scientific Cancer Genetics Inc. Sysmex Corporation Epigenomics AG BioMerieux SA Skyline DX B.V.